Innoviva, Inc. INVA
Innoviva, Inc. (Nasdaq: INVA) is an infectious disease drug developer. Its lead program, Giapreza / Xacduro / Xerava / Zevtera / Nuzolvence (marketed anti-infective and critical-care portfolio), is marketed for Serious infections; vasodilatory shock.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Nuzolvence (zoliflodacin) | Gonorrhea | small molecule | Approved |
| Giapreza | Septic shock | protein/peptide | Approved |
| Xacduro | HABP/VABP (Acinetobacter) | small molecule | Approved |
| Xerava | cIAI | small molecule | Approved |
| Zevtera | SAB/ABSSSI/CABP | small molecule | Approved |
Recent results and decisions
- Feb 25, 2026approval FDA approved NUZOLVENCE (zoliflodacin) in December 2025 for uncomplicated urogenital gonorrhea in adults and pediatric patients 12 and older weighing at least 35 kg; commercialization planned 2H 2026.
In December 2025, IST received U.S. Food and Drug Administration (FDA) approval of NUZOLVENCE® for the treatment of uncomplicated urogenital gonorrhea.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other approved infectious disease companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.